行情

GLYC

GLYC

GlycoMimetics
NASDAQ

实时行情|Nasdaq Last Sale

6.50
+0.24
+3.83%
已收盘, 16:41 11/14 EST
开盘
6.53
昨收
6.26
最高
6.69
最低
6.28
成交量
29.08万
成交额
--
52周最高
13.56
52周最低
2.640
市值
2.82亿
市盈率(TTM)
-4.9194
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GLYC 新闻

  • 京东第三季度净收入同比增28.7% 核心指标加速增长
  • 新浪财经.1小时前
  • 阿里巴巴屁股后为何带"-SW"?港股小尾巴是怎么回事?
  • 新浪网.1小时前
  • 京东第三季度净利润为31亿元 同比增长160.6%
  • 新浪科技.1小时前
  • 阿里香港发行价不高于188港元 集资额高至137亿美元
  • 新浪财经-自媒体综合.1小时前

更多

所属板块

生物技术和医学研究
-0.05%
制药与医学研究
-0.27%

热门股票

名称
价格
涨跌幅

GLYC 简况

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
展开

Webull提供GlycoMimetics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。